Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT03664609
Recruiting Observational

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

NCT03664609 · tracked via the Priya Life Science USA tracker
Sponsor
Boston Scientific Corporation
Phase
Observational
Started
2019-03-12
Last updated
2026-10-07

Condition(s) studied

Parkinson DiseaseEssential TremorDystonia

Investigational drug(s) / intervention(s)

Deep Brain Stimulation

Deep Brain Stimulation: Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.

Study summary

The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Must be previously treated with or eligible for implantation with a deep brain stimulation system Exclusion Criteria: * No Exclusion Criteria

Primary outcome measure(s)

  • Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline — 5 yrs. post implant
    Improvement in disease symptoms as assessed by Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline

Trial sites (20)

FacilityCityRegionStatus
St. Joseph's Hospital & Medical Center Phoenix Arizona Recruiting
Riverside University Health System Moreno Valley California Recruiting
University of California, San Francisco San Francisco California Recruiting
University of Miami Hospital Miami Florida Recruiting
University of South Florida Tampa Florida Recruiting
St. Luke's Regional Medical Center Boise Idaho Completed
Albany Medical Center Albany New York Completed
Wake Forest University School of Medicine Winston-Salem North Carolina Recruiting
Allegheny General Hospital Pittsburgh Pennsylvania Recruiting
Swedish Neuroscience Institute Seattle Washington Completed
AZ St. Lucas Ghent Belgium Recruiting
AZ Delta Roeselare Belgium Recruiting
Hopital Fondation Adolphe de Rothschild Paris France Recruiting
Uniklinik Köln Cologne Germany Recruiting
Universitaetsklinikum Dusseldorf Düsseldorf Germany Recruiting
Uniklinikum Jena Jena Germany Completed
Universitaetsklinikum Schleswig-Holstein Lübeck Germany Recruiting
Universitaetsklinikum Wuerzburg Würzburg Germany Recruiting
Fondazione Istituto Neurologico Casimiro Mondino Pavia Italy Recruiting
Hospital Virgen Del Rocio Seville Spain Recruiting

More Boston Scientific Corporation trials in the USA

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM Recruiting
Intra-operative Pancreatoscopy in Patients With IPMN Active, not recruiting
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation Active, not recruiting
CHAMPION-AF Clinical Trial Active, not recruiting
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing Active, not recruiting

Other trials for the same condition

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD) Active, not recruiting
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease Recruiting
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease Recruiting
Phase 1/2a Study of ANPD001 in Parkinson Disease Enrolling by invitation
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders: Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03664609 on ClinicalTrials.gov ↗ ← All trials in the USA